Lynparza in Combination with Abiraterone Recommended for Approval in the EU by CHMP as 1st-Line Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer

AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been recommended for marketing authorization in the European Union (EU) for the treatment of adult patients with mCRPC for whom chemotherapy is not clinically indicated.